The Role of Trastuzumab in Patients with HER2 Positive Small (pT1mi/a) Breast Cancers, a Multicenter Retrospective Study.
HER2 positive
breast cancer
pT1mic-pT1a
trastuzumab
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Nov 2021
21 Nov 2021
Historique:
received:
27
09
2021
revised:
12
11
2021
accepted:
19
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
The treatment with adjuvant Trastuzumab in patients diagnosed with HER2+ small breast cancers is controversial: limited prospective data from randomized trials is available. This study aims to measure the effect of Trastuzumab in the early stages of breast cancer (pT1mic/a pN0/1mi) in terms of disease recurrence and to identify which are the factors that most affect the prognosis of small HER2+ tumors. One hundred HER2+ pT1mic-pT1a breast cancer patients who were treated in three Turin Breast Units between January 1998 and December 2018 were retrospectively selected and reviewed. Trastuzumab was administered to 23 patients. Clinicopathological features and disease-free survival (DFS) were compared between different subgroups. The primary outcome was the disease recurrence rate. Median follow-up time was 86 months. Compared to pT1a tumors, pT1mic lesions had a higher tumor grade (84% of pT1mic vs. 55% of pT1a;
Identifiants
pubmed: 34830989
pii: cancers13225836
doi: 10.3390/cancers13225836
pmc: PMC8616482
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
J Clin Oncol. 2015 Aug 20;33(24):2600-8
pubmed: 26101239
Crit Rev Oncol Hematol. 2018 Aug;128:130-138
pubmed: 29730143
Breast Cancer Res Treat. 2011 Jun;127(3):713-20
pubmed: 21452022
PLoS One. 2014 Jan 02;9(1):e83646
pubmed: 24392090
BMC Cancer. 2007 Aug 08;7:153
pubmed: 17686164
Am J Clin Pathol. 2021 Jun 17;156(1):155-165
pubmed: 33491064
Breast Cancer Res Treat. 2012 Nov;136(1):289-93
pubmed: 22956007
Cancer Invest. 2020 Feb;38(2):113-121
pubmed: 31939679
Ann Transl Med. 2020 Mar;8(5):187
pubmed: 32309334
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949
J Clin Oncol. 2007 Nov 1;25(31):4952-60
pubmed: 17971593
J Clin Oncol. 2014 Jul 10;32(20):2151-8
pubmed: 24888815
Med Oncol. 2011 Jun;28(2):401-8
pubmed: 20195801
Arch Gynecol Obstet. 2016 Aug;294(2):377-84
pubmed: 26894302
Lancet Oncol. 2021 Aug;22(8):1139-1150
pubmed: 34339645
Ann Surg Oncol. 2011 May;18(5):1342-8
pubmed: 21042943
Eur J Surg Oncol. 2019 Feb;45(2):147-152
pubmed: 30482543
Ann Oncol. 2011 Jan;22(1):17-23
pubmed: 20566473
Semin Oncol. 1999 Aug;26(4 Suppl 12):71-7
pubmed: 10482196
J Clin Oncol. 2014 Jul 10;32(20):2142-50
pubmed: 24888816
Clin Breast Cancer. 2015 Aug;15(4):277-84
pubmed: 25676930
Sci Rep. 2017 Feb 06;7:42045
pubmed: 28165014
Cancer. 2002 Apr 15;94(8):2134-42
pubmed: 12001109
N Engl J Med. 2016 Oct 13;375(15):1438-1447
pubmed: 27732805
Cancer Med. 2014 Feb;3(1):134-42
pubmed: 24407937
Health Policy. 2015 Feb;119(2):212-6
pubmed: 25523144
Ann Surg Oncol. 2013 Aug;20(8):2576-81
pubmed: 23468047
Breast. 2013 Oct;22(5):793-8
pubmed: 23489757
Int J Clin Oncol. 2012 Apr;17(2):131-6
pubmed: 21681642
J Breast Cancer. 2018 Jun;21(2):197-205
pubmed: 29963116
Med Oncol. 2012 Dec;29(4):2586-93
pubmed: 22415399
J Clin Oncol. 2006 May 1;24(13):2113-22
pubmed: 16648513